Peter D. Senter
Impact in
- Radiology, Nuclear Medicine and Imaging top 0.02%
- Monoclonal and Polyclonal Antibodies Research
- Oncology top 0.1%
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
Papers in
-
- Monoclonal and Polyclonal Antibodies Research 88
- Radiopharmaceutical Chemistry and Applications 12
- Oncology 88
- HER2/EGFR in Cancer Research 73
- Peptidase Inhibition and Analysis 15
- CAR-T cell therapy research 15
- Cancer Treatment and Pharmacology 12
- Co-authors
- Eric L. Sievers (3 shared papers)Anna M. Wu (1 shared paper)Stephen C. Alley (13 shared papers)Damon L. Meyer (18 shared papers)Nicole M. Okeley (21 shared papers)Charles G. Cerveny (15 shared papers)Svetlana O. Doronina (22 shared papers)Alan F. Wahl (12 shared papers)
- Journals
- Cancer Research (27 papers)Bioconjugate Chemistry (19 papers)Blood (7 papers)Molecular Cancer Therapeutics (7 papers)Clinical Cancer Research (7 papers)
- Partner nations
- United StatesGermanyBelgium
In The Last Decade
Peter D. Senter
129 papers receiving 13.4k citations
Peter D. Senter's Hit Papers
Peers
Comparison fields: 5 of 131
- Radiology, Nuclear Medicine and Imaging 7.4k
- Oncology 7.4k
- Immunology and Allergy 498
- Immunology 1.7k
- Molecular Biology 5.6k
Countries citing papers authored by Peter D. Senter
This map shows the geographic impact of Peter D. Senter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter D. Senter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter D. Senter more than expected).
Fields of papers citing papers by Peter D. Senter
This network shows the impact of papers produced by Peter D. Senter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter D. Senter. The network helps show where Peter D. Senter may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter D. Senter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 133 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate Hit paper breakdown → | 2004 | 983 |
| 2 | Development of potent monoclonal antibody auristatin conjugates for cancer therapy Hit paper breakdown → | 2003 | 963 |
| 3 | Arming antibodies: prospects and challenges for immunoconjugates Hit paper breakdown → | 2005 | 875 |
| 4 | cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity Hit paper breakdown → | 2003 | 725 |
| 5 | Antibody-Drug Conjugates in Cancer Therapy Hit paper breakdown → | 2012 | 631 |
| 6 | The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Hit paper breakdown → | 2012 | 623 |
| 7 | Antibody–drug conjugates: targeted drug delivery for cancer Hit paper breakdown → | 2010 | 556 |
| 8 | Antibody–drug conjugates come of age in oncology Hit paper breakdown → | 2023 | 532 |
| 9 | Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index Hit paper breakdown → | 2015 | 425 |
| 10 | 2005 | 419 | |
| 11 | Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates Hit paper breakdown → | 2014 | 386 |
| 12 | 2008 | 384 | |
| 13 | 2008 | 341 | |
| 14 | 2007 | 331 | |
| 15 | 2009 | 326 | |
| 16 | 2005 | 318 | |
| 17 | 2010 | 313 | |
| 18 | 2004 | 313 | |
| 19 | 2013 | 309 | |
| 20 | 2004 | 231 |
About Peter D. Senter
Peter D. Senter is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Molecular Biology, Immunology and Organic Chemistry, having authored 133 papers that have together received 14.3k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (88 papers), HER2/EGFR in Cancer Research (73 papers), Glycosylation and Glycoproteins Research (20 papers), Peptidase Inhibition and Analysis (15 papers), CAR-T cell therapy research (15 papers), Cancer Treatment and Pharmacology (12 papers), Radiopharmaceutical Chemistry and Applications (12 papers) and Cancer therapeutics and mechanisms (10 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (7.4k citations), Oncology (7.4k citations), Immunology and Allergy (498 citations), Immunology (1.7k citations) and Molecular Biology (5.6k citations). Peter D. Senter has collaborated with scholars based in United States, Germany and Belgium. Frequent co-authors include Eric L. Sievers, Anna M. Wu, Stephen C. Alley, Damon L. Meyer, Nicole M. Okeley, Charles G. Cerveny, Svetlana O. Doronina, Alan F. Wahl, Joseph A. Francisco and Brian E. Toki. Their work appears in journals such as Cancer Research, Bioconjugate Chemistry, Blood, Molecular Cancer Therapeutics and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.